Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
47 hedge funds and large institutions have $80.2M invested in Carisma Therapeutics in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 14 closing their positions.
80% more call options, than puts
Call options by funds: $1.52M | Put options by funds: $844K
2% more funds holding
Funds holding: 46 → 47 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
3% more capital invested
Capital invested by funds: $78.2M → $80.2M (+$2.02M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.2% less ownership
Funds ownership: 2.62% → 2.42% (-0.2%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
+$2.29M |
| 2 |
Millennium Management
New York
|
+$1.62M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.52M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$886K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$351K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.12M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.8M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.38M |
| 5 |
AWS
AJ Wealth Strategies
New York
|
-$400K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Two Sigma Investments
New York
| – | -$77K | -1,985 | Closed |
|
52
Barclays
London,
United Kingdom
| – | -$63K | -1,615 | Closed |
|
53
Goldman Sachs
New York
| – | -$37K | -953 | Closed |
|
54
Parallax Volatility Advisers
San Francisco,
California
| – | -$35.3K | -907 | Closed |
|
55
State Street
Boston,
Massachusetts
| – | -$22K | -575 | Closed |
|
|
TSS
56
Two Sigma Securities
New York
| – | -$22K | -573 | Closed |
|
|
PAM
57
Panagora Asset Management
Boston,
Massachusetts
| – | -$18K | -462 | Closed |
|
|
RA
58
Royce & Associates
New York
| – | -$5K | -132 | Closed |
|
59
Bank of America
Charlotte,
North Carolina
| – | -$3K | -85 | Closed |
|
60
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$2K | -55 | Closed |
|
61
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$39 | +1 | New |
|
CARM Hedge Fund Activity: Q3 2018 in Review
47 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2018, worth a combined $80.2M — up 2.6% from $78.2M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CARM positions and 14 closed out — a net gain of 1 holder — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Nexthera Capital, opening a new position worth an estimated $2.29M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $5.12M sold.
- 47 institutional investors held Carisma Therapeutics (CARM) as of Q3 2018, up from 46 in Q2 2018.
- Funds reported $80.2M of Carisma Therapeutics stock for Q3 2018, up 2.6% quarter-over-quarter.
- 15 funds opened new Carisma Therapeutics positions in Q3 2018 and 14 closed out, a net change of +1 holder.
- The largest Carisma Therapeutics buyer in Q3 2018 was Nexthera Capital, an estimated $2.29M added.
- The largest Carisma Therapeutics seller in Q3 2018 was Baker Bros. Advisors, an estimated $5.12M sold.
Based on aggregated 13F filings for Q3 2018.